Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10189823 Neprilysin inhibitors

Patent 10189823 was granted and assigned to Theravance on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Theravance
Theravance
Date Filed
December 14, 2017
Date of Patent
January 29, 2019
Patent Applicant
Theravance
Theravance
Patent Application Number
15841749
Patent Citations Received
‌
US Patent 11919888 Neprilysin inhibitors
0
‌
US Patent 10570120 Neprilysin inhibitors
‌
US Patent 10752599 Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
‌
US Patent 11634413 Neprilysin inhibitors
0
‌
US Patent 11230536 Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
‌
US Patent 10472335 Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10189823
Patent Primary Examiner
‌
Kamal A Saeed

Find more entities like US Patent 10189823 Neprilysin inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo